The Progress and Prospect of Boron Neutron Capture Therapy

doi:10.7538/tws.2017.youxian.061

Abstract

Abstract:

Boron neutron capture therapy (BNCT) is a kind of radiotherapy that can selectively kill tumor cells. After being carried into the human body, the Boron (¹⁰B) compound will be selectively enriched in tumor cells, reacting with the neutron, and release α particles and ⁷Li particles to kill the tumor. BNCT has become a new method in the field of radiation therapy because of its targeted treatment, low toxicity and high efficiency. Since the last century, boron neutron capture therapy has emerged in various countries and gradually developed. It has been able to successfully treat glioma, melanoma and other diseases. Recently, BNCT is faced with some problems that develop innovative and efficient boron-containing drugs, establish more accurate measurement system of boron dose, and how the medical neutron sources get rid of nuclear reactors. This article will briefly summarize and explore the principles, advantages, progress and problems of BNCT.

Key words: boron-neutron capture therapy, boron compounds, tumor cells, neutron source

摘要：

硼中子俘获疗法（boron neutron capture therapy, BNCT）是一种可以选择性杀伤肿瘤细胞的放射疗法，硼(¹⁰B)化合物携带剂注入人体后, 会选择性富集于肿瘤细胞,与中子发生俘获反应，释放α粒子和⁷Li粒子杀死肿瘤。BNCT以靶向治疗、低毒高效等优势成为了放射治疗领域的新型手段。从上世纪开始，硼中子俘获疗法已在世界各国崭露头角并逐渐发展起来，已经能够成功治疗脑胶质瘤、黑色素瘤等多种疾病。目前，BNCT面临着如何研发创新更高效的含硼药物，建立更为精确的硼剂量测量体系，以及医用中子源如何摆脱核反应堆等问题。本文对BNCT的原理、优势、进展以及所面临的问题进行简要综述与探究。

关键词: 硼中子俘获疗法, 硼化合物, 肿瘤细胞, 中子源

WANG Miao;TONG Yongpeng. The Progress and Prospect of Boron Neutron Capture Therapy[J]. Journal of Isotopes, 2020, 33(1): 14-26.

王淼;童永彭. 硼中子俘获治疗的进展及前景[J]. 同位素, 2020, 33(1): 14-26.

References

［1］周幽心，孙婷，杨伟廉，等. 硼中子俘获治疗人脑胶质母细胞瘤的前景和困惑［J］. 中国工程科学，2012，8(3)：82-84.Zhou Youxin, Sun Ting, Yang Weilian, et al. Boron neutron capture therapy for glioblastoma of prospects and confused［J］. Engineering Science, 2012, 8(3): 82-84(in Chinese).
［2］赵修良，金晓峰，程晓龙，等. 硼中子俘获治疗中血硼浓度的测量方法［J］. 科技导报，2014，32(17)：71-75.Zhao Xiuliang, Jin Xiaofeng, Cheng Xiaolong, et al. Development of blood boron concentration measurement in boron neutron capture therapy［J］. Science ＆Technology Review, 2014, 32(17): 71-75(in Chinese).
［3］王晓易.七成以上肿瘤患者需要进行放疗［EB/OL］.（2017-12-12）［2018-03-31］. http:∥news.163.com/10/1123/14/6M6ALESK00014JB6.html.
［4］Bilski P, Budzanowski M, Ochab E, et al. Dosimetry of BNCT beams with novel thermoluminescent detectors［J］. Radiation Protection Dosimetry, 2004,110 (1-4) :623-626.
［5］Bilski P, Golnik N, Olko P, et al. lmproved dosimetry for BNCT by activation foils,mndlfled thermoluminescent detectors and recombination chambers［J］. NUKLEONIKA, 2004, 49(2): 51-56.
［6］曹明富,应蓓蓓,徐人尔,等. 肿瘤坏死因子α和β对电离辐射诱导细胞凋亡的效应［J］. 实验生物学报,2002(3):198-204.Cao Mingfu, Ying Beibei, Xu Rener, et al. Effect of tumor necrosis factor α and β on apoptosis induced by ionizing radiation［J］. Acta Biologiae Experimentalis Sinica, 2002(3): 198-204(in Chinese).
［7］李洪凌. 自由基对肿瘤细胞辐射效应影响的实验研究［D］. 北京:中国疾病预防控制中心，2009:1-40.
［8］Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines［J］. Seminars in Immunology, 2010, 22(3): 113-124.
［9］Formenti S C, Demaria S. Systemic effects of local radiotherapy［J］. Lancet Oncol, 2009, 10(7): 718-726.
［10］江海燕，储德林. 硼中子俘获治癌的技术进展及关键问题［J］. 物理通报，2014,04:114-116.Jiang Haiyan, Chu Delin. The progression and key issues on treatment for cancer by means of boron neutron capture therapy technology［J］. Physics Bulletin, 2014, 4: 114-116(in Chinese).
［11］Betti O O, C Munari, Rosler R. St: 311 ereotactic radiosurgery with the linear accelerator: treatment of arteriovenous malformations［J］.Neurol Surgery,1989(24): 311.
［12］昌爱武. 三维适形放射治疗技术的应用分析［J］. 中外医学研究,2013(17):154-155.Chang Aiwu. Application analysis of three dimensional conformal radiation therapy［J］. Chinese and Foreign Medical Research, 2013(17): 154-155(in Chinese).
［13］席强,涂恒业. 肿瘤放射治疗物理技术新进展［J］. 河北北方学院学报(自然学科版),2013,29(1):114-117.Xi Qiang, Tu Hengye. New advances in physical techniques for radiotherapy of tumors［J］. Journal of Hebei North University (Natural Science Edition), 2013, 29(1): 114-117(in Chinese).
［14］邹海哲. 四维放射治疗技术4D-CT重建技术在肝癌精确放疗定位的应用效果分析［J］. 世界最新医学信息文摘（电子版）,2016(95):38.Zou Haizhe. Application effect of 4D-CT reconstruction technique for accurate radiotherapy of liver cancer［J］. World’s Latest Medical Information Digest (Electronic Edition), 2016(95): 38(in Chinese).
［15］孙艳美，孙婧，程桂娥. 例高龄右桥小脑角区脑膜瘤患者质子放射治疗的护理［J］. 中国实用护理杂志,下旬版,2006,22(12):41-42.Sun Yanmei, Sun Jing, Cheng Gui’e. Nursing care of patients with meningioma in the right cerebellopontine angle area of elderly patients with proton radiotherapy［J］. Chinese Journal of Practical Nursing, 2006, 22(12): 41-42(in Chinese).
［16］谢俊祥. 质子/重离子放射治疗技术及应用［J］. 中国医疗器械信息,2017,23(1):1-4.Xie Junxiang. Proton/Heavy ion radiation therapy and its application［J］. China Medical Device Information, 2017, 23(1): 1-4(in Chinese).
［17］hong Yong, Zewen Song, Yongmao Zhou. Boron neutron capture therapy for malignant melanoma: first clinical case report in China［J］. Chinese Journal of Cancer Research, 2016, 28(6): 634-640.
［18］罗军益，何佳恒. 硼中子俘获疗法治疗肿瘤及相关技术研究进展［J］. 辐射防护通讯,2010,30(2):26-29.Luo Junyi , He Jiaheng. Application of BNCT to tumor therapy［J］. Radiation Protection Bulletin, 2010, 30(2): 26-29(in Chinese).
［19］张紫竹，金从军，刘凯，等. 中子俘获疗法临床应用国际进展［J］. 中国工程科学,2012,9(8):100-105.Zhang Zizhu, Jin Congjun, Liu Kai. Neutron capture therapy clinical development in the world［J］. Engineering Science, 2012, 9(8): 100-105(in Chinese).
［20］Cruickshank G S, Ngoga D, Detta A, et al. A cancer research UK pharma-cokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT［J］. Appl Radiat Isot, 2009, 67(7-8 Suppl): S31-S33.
［21］Kawabata S, Miyatake S, Nonoguchi N, et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients［J］. Appl Radiat Isot, 2009, 67(7/8 suppl): S15-S18.
［22］Miyatake S, Kawabata S, Yokoyama K, et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas［J］. J Neurooncol, 2009, 91(2): 199-206.
［23］Wordenl F P, Moon J, Samlowski W, et al. A phase ll evaluation of a3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of head and neck［J］. Cancer, 2006: 319-327.
［24］Cumberlin R L. Clinical research in neutron capture therapy［J］. Int J Radiat Oncol Biol Phys, 2002, 54(4): 992-998.
［25］Coderre J A. Neutron capture therapy of the 9L gliosarcoma using the p-boronophenylalaanine fructose, lnt［J］. Radiation Oncology Biol, phys, 1994: 643.
［26］Menendez P R, Roth B M C, Pereira M D, et al. BNCT for skinmelanoma in extremities: updated Argentine clinical results［C］∥Zonta A, et al. A New Option Against Cancer: Proceedings of the 14th lntemational Congress on Neutron Capture Therapy. Florence, ltaly, 2010: 7-8.
［27］Sakurai Y, Tanaka H, Takata T, et al. Advances in boron neutron capture therapy (BNCT) at Kyoto University from reactor-based BNCT to accelerator-based BNCT［J］. Journal of the Korean Physical Society, 2015, 67(1): 76-81.
［28］张紫竹. 硼中子俘获疗法关键技术取得突破性进展［J］. 科技成果管理与研究,2017(2):13.Zhang Zizhu. Breakthrough progress in key technologies of boron neutron capture therapy［J］. Scientific and Technological Achievements Management and Research, 2017(2): 13(in Chinese).
［29］叶娟. 积跬步致千里——周永茂谈我国中子照射器首例病患的临床试治［J］.中国核工业,2014,10(9):59-61.Ye Juan. Accumulate a thousand miles-Zhou Yongmao talks about the clinical trials of the first case of neutron irradiation in China［J］. China Nuclear Industry, 2014, 10(9): 59-61(in Chinese).
［30］李大庆. 神奇中子如何定向“引爆”癌细胞［EB/OL］. (2017-08-17)［2018-04-02］. http:∥www. cas.cn/cm/201708/t20170817_4611459.shtml.
［31］周永茂. 迈入新世纪的硼中子俘获疗法(BNCT)［J］. 中国工程科学,2012,9(8):4-13.Zhou Yongmao. The boron neutorn capture therapy (BNCT) status to go into the new era［J］. Engineering Science, 2012, 9(8): 4-13(in Chinese).
［32］高峰，苑娇梅. 硼中子俘获治疗药物的研究进展［J］. 中国新药杂志,2010,19(4):296-300.Gao Feng, Yuan Jiaomei. Advances in drugs used in boron neutron capture therapy［J］. Chinese Journal of New Drugs , 2010, 19(4): 296-300 (in Chinese).
［33］Yang W, Barth B F. Molecular targeting of the epidermal growth factor receptor for BNCT of brain gliomas［R］. Ohio, USA: The Ohio State Universitv, 2011.
［34］Nedunchezhian K, Aswath N, Thiruppathy M, et al. Boron neutron capture therapy-a literature review［J］. Journal of Clinical and Diagnostic Research , 2016, 10（12）: 1-4.
［35］Aris, Zonta. BNCT: a new option against cancer, president’s address. Proc. 13th International Congress on NCT. Florence, 2008, 2(7): 5-6.
［36］Kawabata S, Miyatake S, Hiramatsu R, et al. Phase Ⅱ clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme-study design and current status report［J］. Appl Radiat Isot, 2011, 69: 1796-1799.
［37］Barth R F. Boron neutron capture therapy at the crossroads: challenges and opportunities［J］. Appl Radiat Isot, 2009 , 67: 3-6.
［38］Jianling Wang, Leifeng Chen, Jing Ye, et al. Carborane derivative conjugated with gold nanoclusters for targeted cancer cell imaging［J］. Radiation Oncology, 2017, 18(5): 1466-1472.
［39］Sumitani S,Oishi M ,Yaguchi T, et al. Pharmacokinetics of core polymerized, boron-conjugated micelles designed for boron neutron capture therapy for cancer［J］. Biomaterials, 2012, 33(13): 3568-3577.
［40］代从新,姚勇,王任直. 硼中子俘获疗法治疗脑胶质瘤及难治性垂体腺瘤的现状及展望［J］. 中国工程科学,2012,14(8):96-99.Dai Congxin, Yao Yong, Wang Renzhi. Boron neutron capture therapy of gliomas and refractory pituitary adenomas: current status and future prospects［J］. Engineering Science, 2012, 14(8): 96-99(in Chinese).
［41］Yang W, Barth R, Wu G, et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas［J］. Appl Radiat Isot, 2004, 61(5): 981-985.
［42］Yang W, Wu G, Barth R F, et al. Molecular targeting and treatment of composite EGFR and EGFRvⅢ-positive gliomas using boronated monoclonal antibodies［J］. Clin Cancer Res, 2008, 14(3): 883-891.
［43］Huang W C, Chen Y J, Hung M C. Implication of nuclear EGFR in the development of resistance to anticancer therapies［J］. Biomedicine 2011, 1: 2-10.
［44］Kaniowski D, Ebenryter-Olbi′ nska K, Sobczak M, et al. High boron-loaded DNA-oligomers as potential boron neutron capture therapy and antisense oligonucleotide dual-action anticancer agents［J］. Molecules, 2017, 22: 1393-1413.
［45］Hwang K C, Lai P D, Chiang C S, et al. Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells［J］. Biomaterials, 2010, 31(32): 8419-8425.
［46］Thirumamagal B T, Zhao X B, Bandyopadhyaya A K, et al. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT)［J］. Bioconjug Chem, 2006, 17(5): 1141-1150.
［47］Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy［J］. Adv Drug Deliv Rev, 2004, 56(8):1067-1084.
［48］Ross J F, Chaudhuri P K, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant-tissures in-vivo and in established cell-lines-physiological and clinical implications［J］. Cancer, 1994, 73 (9): 2432-2443.
［49］Gabizon A, Horowitz A T, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)grafted liposomes: in vitro studies［J］. Bioconjug Chem, 1999,10 (2) : 289-298.
［50］Barth R F, Coderre J A, Vicente M G, et al. Boron neutron capture therapy of cancer: current status and future prospects［J］. Clin Cancer Res, 2005, 11: 3987-4002.
［51］Liu X, Ma S, Yao Y, et al. Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior［J］. Neurosurgery, 2012, 70: 1274-1280.
［52］Pantarotto D, Singh R, McCarthy D, et al. Functionalized carbon nanotubes for plasmid DNA gene delivery［J］. Angew Chem Int Ed, 2004, 43(39): 5242-5246.
［53］Kam N W S, Liu Z, Dai H J. Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway［J］. Angew Chem Int Ed, 2006, 45 (4): 577-581.
［54］Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice［J］. Nat Nanotech, 2007, 2(1): 47-52.
［55］Yinghuai Z, Peng A T, Carpenter K, et al. Substituted carborane-appended water-soluble single-wall carbon nanotubes: new approach to boron neutron capture therapy drug delivery［J］. J Am Chem Soc, 2005, 127(27): 9875-9880.
［56］Mortensen M W, Bjorkdahl O, Sorensen P O, et al. Functionalization and cellular uptake of boron carbide nanoparticles: the first step toward T cell-guided boron neutron capture therapy［J］. Bioconjug Chem, 2006, 17(2): 284-290.
［57］Hiramatsu R, Kawabata S, Miyatake S, et al. Application of a novel boronated porphyrin (H2OCP) as a dual sensitizer for both PDT and BNCT［J］. Lasers Surg Med, 2011, 43(1): 52-58.
［58］Gottumukkala V, Luguya R, Fronczek F R, et al. Synthesis and cellular studies of an octa-anionic 5, 10, 15, 20-tetra［3, 5-( nido-carboranylmethyl) phenyl］ porphyrin (H(2) OCP) for application in BNCT［J］. Bioorg Med Chem, 2005, 13(5): 1633-1640.
［59］Vicente M G H, Sibrian-Vazquez M. Syntheses of boronated porphyrins and their application in BNCT［J］. World Scientific Publishers, 2010, 4: 191-248.
［60］Renner M W, Miura M, Easson M W, et al. Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy［J］. Anticancer Agents Med Chem, 2006, 6(2): 145-157.
［61］Stummer W, Novotny A, Stepp H, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinicacid-inducedporphyrins: Aprospective study in 52 consecutive patients［J］. J Neurosurg, 2000,93(6): 1003-1013.
［62］Hao E, Sibrian-Vazquez M, Serem W, et al. Synthesis, aggregation and cellular investigations of porphyrin-cobaltacarborane conjugates［J］. Chemistry, 2007, 13(32): 9035-9042.
［63］Kobayashi N, Allen N, Clendenon N R, et al. Animprovedrat brain-tumor model［J］. J Neurosurg, 1980, 53(6): 808-815.
［64］Choi K Y, Saravanakumar G, Park J H, et al. Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer［J］. Colloids Surf B Biointerfaces, 2012, 99: 82-94.
［65］Toole B P. Hyaluronan: from extracellular glue to pericellular cue［J］. Nat Rev Cancer, 2004 , 4: 528-539.
［66］Auvinen P, Tammi R, Parkkinen J, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival［J］. Am J Pathol, 2000, 156: 529-536.
［67］Setala L P, Tammi M I, Tammi R H, et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate［J］. Br J Cancer, 1999, 79: 1133-1138.
［68］Demina T S, Akopova T A, Vladimirov L V, et al. The study of the interaction between chitosan and 2, 2-Bis (hydroxymethyl) propionic acid during solid-phase synthesis［J］. Polym Sci Ser B, 2011 , 53: 358-370.
［69］Van den Berg R, Peters J A, van Bekkum H. The structure and (local) stability constants of borate esters of mono- and di-saccharides as studied by ¹¹B and ¹³C NMR spectroscopy［J］. Carbohyd Res,1994, 253: 1-12.
［70］罗全勇,朱瑞森. 硼中子俘获治疗［J］. 同位素,2004,17(3):174.Luo Quanyong, Zhu Ruisen. Boron neutron capture therapy［J］. Journal of Isotopes, 2004, 17(3): 174(in Chinese).
［71］Henriksson R, Capala J, Michanek A, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase Ⅱ study evaluating a prolonged high-dose of boronophenylalanine (BPA)［J］. Radiother Oncol, 2008, 88: 183-191.
［72］Yongpeng Tong. A novel EGFR-TKI inhibitor (cAMP-H3BO3 complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes［J］. Oncotarget. 2017, DOI: 10.18632/oncotarget.17628.
［73］Barth R F, Vicente M G, Harling O K, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer［J］. Radiant Oncol, 2012, 7: 146-166.
［74］曹勤剑,郑建国,刘立业. 硼中子俘获治疗（BNCT）及剂量测量方法［J］. 中国辐射卫生,2016(2):221-224.Cao Qinjian, Zheng Jianguo, Liu Liye. Boron neutron capture therapy (BNCT) and dose measurement methods［J］. Radiation Health in China, 2016(2): 221-224.
［75］Kono Y, Kurihara H, Kawamoto H, et al. Radiation absorbed dose estimates for ¹⁸F BPA PET［J］. Original Article, 2017, 58(9): 1094-1100.
［76］Hatanaka H, Nakagawa Y. Clinical results of lonb surviving brain tumor patients who underwent boron neutron capture therapy［J］. International Journal of Radiation Oncology Biology Physics, 1994, 28(5): 1061-1066.
［77］Tang Xiuhuan, Jiang Xinbiao, Want Peng, et al. Research on method of detecting microscopic distribution of boron in sub-cellular tissue［J］. Atomic Energy Science and Technology, 2008, 42(6): 81-87.
［78］Zhao Zhumin, Zhang Liang, Jiang Xinbiao, et al. Calculation of IHNI-1 reactor core's neutronics parameters［J］. Science & Technology Review,2012, 30(20): 48-51.
［79］Peng Dan, Lu Jin, Zou Shuyun, et al. Measurement of thermal neutron fluence rate of in-hospital neutron irradiator by ssntd［J］. Atomic Energy Science and Technology, 2013, 47(8): 1368-1370.
［80］王静娟. 一体化PET/MR在脑功能方面的研究进展［J］. 医学影像学杂志,2017,27(9):1798-1799.Wang Jingjuan. Progress of hybrid PET/MR in brain function study［J］. Journal of Medical Imaging，2017, 27(9): 1798-1799(in Chinese).
［81］彭猛. 硫中子俘获治疗中子源技术研究［D］. 兰州：兰州大学,2017：1-63.
［82］江新标,张文首,高集金,等. 低浓化医院中子照射器（IHNI-1）堆芯的物理方案设计［J］. 中国工程科学,2009,11(11):17-21.Jing Jinbiao, Zhang Wenshou, Gao Jijin, et al. Design of physical scheme for core of low concentration hospital neutron illuminator (IHNI-1)［J］. China Engineering Science, 2009, 11(11): 17-21(in Chinese).
［83］Dai Congxin, Cai Feng, Hwang Kuochu. Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas［J］. Science China Life Sciences, 2013, 56(2): 163-173.
［84］刘勇，陈一璋，小野公二，等. 细胞水平的放疗:硼中子俘获疗法介绍［J］. 中华临床医师杂志,2011,5(22):6699-6702.Liu Yong, Chen Yizhang, Xiao Yegonger, et al. Cellular radiotherapy: introduction to boron neutron capture therapy［J］. Chinese Journal of Clinicians, 2011, 5(22): 6699-6702(in Chinese).
［85］Bortolussi S, Postuma I, Protti N, et al. Understanding the potentiality of accelerator based boron neutron capture therapy for osteosarcoma: dosimetry assessment based on the reported clinical experience［J］. Radiation Oncology, 2017, 10(12):86-91.
［86］刘政. 基于中子管中子发生器的硼中子俘获癌症治疗法的可行性研究［D］. 吉林：东北师范大学，2015:1-49.
［87］陈启亮. 中国5年内有望实现癌细胞“精准清除”［EB/OL］. (2017-08-11)［2018-04-02］. http:∥www.dzwww.com/xinwen/shehuixinwen/201708/t20170812_16281644.htm.
［88］Koltay E. Investigation on the excitation function of the nuclear reaction ⁹Be(d, n)¹⁰B, by artificially accelerated particles in the 0, 5-1, 6 MeV energy range［J］. Acta physical Academic Scientiarum Hungaricae, 1963, 16(2):93-100.
［89］Brune C R, Kavanagh R W. Total cross sections and thermonuclear reaction rates for ¹³C (d,n) and ¹⁴C (d,n)［J］. Physical Review C, 1992, 45(3): 1382-1388.

[1]	ZHANG Feng;TIAN Lili. Research Development and Tendency of Controllable Neutron and X-ray Source Well Logging Technology [J]. Journal of Isotopes, 2019, 32(3): 133-150.
[2]	ZHANG Feng;LIUJun-tao;YUAN Chao;JIA Yan;YU Hua-wei. Monte Carlo Simulation of Determining Porosity by Using Dual Gamma Detectors [J]. Journal of Isotopes, 2013, 26(2): 104-109.
[3]	ZHANG Feng;YUAN Chao;HUANG Long-ji. Technology and Application Development of Isotopic Neutron Source Well Logging in China [J]. Journal of Isotopes, 2011, 24(1): 12-19.
[4]	ZHANG Feng;JIN Xiu-yun;HOU Shuang. Monte Carlo Simulation on Compensated Neutron Porosity Logging in LWD With D-T Pulsed Neutron Generator [J]. Journal of Isotopes, 2010, 23(1): 15-21.
[5]	. Polonium and Radium Led the Development of [J]. Journal of Isotopes, 2008, 21(4): 241-.
[6]	. Fast Neutron Imaging Using 241Am-Be Neutron Source [J]. Journal of Isotopes, 2007, 20(2): 87-90.
[7]	. Neutron Activation Analysis of Nickel Concentrates Samples With ~(252)Cf Neutron Source [J]. Journal of Isotopes, 2005, 18(3 ): 129-129 .
[8]	. ANALYSIS OF THE DEVIATION OF ~(210)Po CALORIMETRY MEASUREMINTS [J]. Journal of Isotopes, 1992, 5 (3 ): 153-153 .
[9]	. DETERMINATION OF ANISOTROPIC COEFFICIENTS OF RADIONUCLIDE NEUTRON SOURCE [J]. Journal of Isotopes, 1992, 5 (1 ): 20-20 .
[10]	. ~(241)Am-Be NEUTRON SOURCE AND ITS APPLICATION [J]. Journal of Isotopes, 1990, 3 (1 ): 65-65 .